Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples